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The peroxisome proliferator-activated receptors (PPARs) are central regulators of fat metabolism, energy homeostasis,
proliferation, and inﬂammation. The three PPAR subtypes, PPARα, β/δ,a n dγ activate overlapping but also very diﬀerent target
gene programs. This review summarizes the insights into PPAR subtype-speciﬁc transactivation provided by genome-wide studies
and discusses the recent advances in the understanding of the molecular mechanisms underlying PPAR subtype speciﬁcity with
special focus on the regulatory role of AF-1.
1.Introduction
T h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o r s( P P A R s )
c o n s t i t u t eas u b g r o u po ft h en u c l e a rr e c e p t o r( N R )f a m i l y .
The founding member of the family, PPARα,w a si d e n t i ﬁ e d
in 1990 and named by its ability to become activated by
chemicals known to induce peroxisome proliferation in
rodents [1]. Subsequently, the two other PPAR subtypes,
PPARβ/δ and PPARγ, were identiﬁed by homology screens
[2, 3]. The three PPAR subtypes are encoded by distinct
genes located on diﬀerent chromosomes (reviewed by [4]).
Alternate promoter usage and splicing give rise to two dif-
ferent protein isoforms from the PPARγ gene called PPARγ1
and PPARγ2, with the latter containing 30 additional amino
acidsattheN-terminus(Swiss-Prothttp://www.expasy.org/).
All three PPAR subtypes can be activated by a large
variety of fatty acids and fatty acid metabolites, such as
hydroxylated eicosanoids, prostaglandins, and leukotrienes,
and by many synthetic compounds. PPARα is speciﬁcally
activated by ﬁbrates and other hypolipidemic drugs, whereas
PPARγ is activated by the insulin-sensitizing, antidiabetic
thiazolidinedione drugs [4].
The PPARs play important regulatory roles in numerous
cellular processes related to metabolism, inﬂammation,
diﬀerentiation, proliferation, and atherosclerosis (reviewed
by [5, 6]). The three subtypes display dissimilar patterns
of tissue distribution and activate both overlapping and
distinct sets of target genes. Most notably, whereas PPARα
[7, 8]a n d- β/δ [9] are potent activators of genes involved
in lipid oxidation, PPARγ stands out by its additional ability
to activate lipogenic genes and adipocyte diﬀerentiation [10,
11]. In fact, PPARγ is obligate for adipocyte diﬀerentiation
and is suﬃcient to transform many nonadipogenic cell lines
into adipocyte-like cells [12, 13]. As a reﬂection of these
subtype-speciﬁc properties, PPARα and PPARβ/δ are highly
expressed in tissues with high β-oxidation rates such as
liver, muscle, heart, and brown adipose tissue. By contrast
PPARγ is highly expressed in adipose tissue, and PPARγ2
is fat selective, whereas the PPARγ1 isoform is expressed at
low levels in several tissues, including colon, spleen, liver,
and muscles. PPARβ/δ is the most ubiquitously expressed
subtype with the highest levels found in the intestines and
keratinocytes (see [14]a n dr e v i e w e db y[ 5]).
Like most NRs, the PPAR protein structure consist of
four domains: The N-terminal A/B-domain containing the
ligand-independent activation function 1 (AF-1), the C-
domain, which is the DNA-binding domain (DBD), the D-
domain, also called the hinge region, and ﬁnally the E-
domain, commonly referred to as the ligand binding domain
(LBD). The E-domain contains the ligand-dependent AF-
2, which is highly dependent on the C-terminal helix 12.
While the A/B -and D-domains are only poorly conserved2 PPAR Research
between the PPAR subtypes, the C -and E-domains share a
high degree of sequence and structural homology (reviewed
by [4]). In fact, the C-domains are completely interchange-
able between the PPAR subtypes and appear to have no
eﬀect on speciﬁcity [15, 16]. The PPARs bind DNA as
obligate heterodimers with members of the retinoid X
receptor(RXR)familyofnuclearreceptorstomodiﬁeddirect
repeat 1 elements (DR1) with the consensus sequence 5-
AACTAGGNCA A AGGTCA-3. The PPARs occupy the 5
extended half site of the binding site [17].
Given the important role of the PPARs in regulation
of metabolism, inﬂammation, diﬀerentiation, and cellular
growth, a large number of speciﬁc and potent synthetic
ligands have been generated. This has spurred a huge
interest in understanding the molecular mechanisms of
PPAR transactivation and in genome-wide approaches to
identify new PPAR target genes. These studies have provided
the ﬁeld with important insights into how diﬀerent ligands
modulate the transactivation capacity of the PPARs and
to what extent the individual PPAR domains are involved
in ensuring subtype-speciﬁcity by enabling or preventing
transactivation of speciﬁc subsets of target genes. This paper
focuses on the recent advances in understanding PPAR
subtype-speciﬁc transactivation as seen from a molecular
and a genome-wide perspective. In particular, the regulatory
roleoftheAF-1inmaintainingPPARsubtype-speciﬁcityand
transactivation capacity is reviewed.
2.MolecularMechanismsof PPARSubtype
SpeciﬁcTransactivation
The ability of the individual PPAR subtypes to induce very
diﬀerent cellular fates is intriguing because they share a high
degree of sequence- and structural homology and activate
overlapping sets of target genes. Nevertheless, the PPARs
maintainahighdegreeofsubtype-speciﬁcitywhenexpressed
in a given cell line at comparable levels [11, 18, 19]a n d
adenoviral expression of PPARγ1 in mouse liver leads to
induction of several genes which are not readily activated
by PPARα, that is, genes involved in lipid accumulation
and adipogenesis [20]. These results indicate that although
the chromatin setting ultimately determines the accessibility
of the PPAR response elements, intrinsic properties of the
individual PPAR subtypes are key determinants of the gene
programs that can be activated. Mechanisms maintaining
subtype-speciﬁcity are of signiﬁcant general interest because
subtype selective gene regulation is a recurrent theme among
transcription factor families, and therefore several attempts
have been made to address this issue. These studies reported
that the PPAR subtypes diﬀer only little in their ability
to transactivate artiﬁcial promoter reporter constructs in
transienttransfections[21–24]anddisplaylimitedspeciﬁcity
in their binding to naked DNA containing target gene PPAR
response elements (PPREs) in mobility shift assays, although
poorlyconservedPPREspreferentiallybindPPARγ:RXRhet-
erodimers [25]. By contrast, work from our laboratory has
shownthatintheendogenouschromatinsetting,thebinding
level of a particular PPAR subtype to a given genomic PPRE
generally correlates with its potential to transactivate the
corresponding target gene, although exceptions clearly exist
[11].
2.1. The LBD and AF-2. Because of the obvious therapeutic
potential for modulating PPAR transactivation through the
administration of ligands that bind to the E-domain, the
cofactor interaction surfaces and the molecular mechanisms
underlying activation of the AF-2 have been extensively
studied. The recent publication of an almost complete
structure of the DNA bound PPARγ:RXRα heterodimer [26]
represents a major breakthrough in the understanding of the
positioning of the PPARγ and RXR domains relative to each
other and their interactions. Unfortunately, the PPARγ and
RXRα A/B-domains could not be crystallized, most likely
due to their high mobility and lack of internal structure.
However, the overall impression from this study is that the
PPARγ LBD is the centerpiece of the complex, around which
all other domains from both PPARγ and RXRα are arranged
[26]. This accentuates previous descriptions of extensive
interdomain cross-talk in the PPARs [27, 28].
The PPARγ LBD, is composed of 13 α-helices and a small
four-stranded β-sheet that forms a large (approx. 1300 ˚ A3)
T-shaped hydrophobic ligand-binding pocket typical for
the promiscuous NRs, such as PPARs and the pregnane
X receptor (PXR), that bind many diﬀerent ligands with
low aﬃnity [29]. The ligand-binding pocket of PPARβ/δ is
narrower than those of PPARγ and PPARα, which appears
to be a major determinant of ligand binding, as it prohibits
binding of TZDs and severely decreases the aﬃnity of
PPARβ/δ towards ﬁbrate ligands due to the bulky acid and
alkyl groups on these compounds [30]. PPARα contains
the most lipophilic ligand binding pocket, which potentially
explains why PPARα,a so p p o s e dt oP P A R β/δ and PPARγ,
binds a variety of saturated fatty acids [31]. An additional
layer of ligand binding speciﬁcity is imposed by the size
and charge of the amino acids lining the ligand binding
pocket[30].Ligand-bindingaﬀectsthestabilityofthePPARs
with liganded PPARα being transiently stabilized [32] while
proteasomal degradation of PPARγ is increased upon ligand
binding [33].
The structural basis for AF-2-mediated transcriptional
activity is a ligand-induced conformational change in the
LBD, causing the most C-terminal helix 12 to fold up against
the core [30]; thereby generating an activation surface,
often described as a charge clamp, onto which coactivators
can dock. Many coactivators bind to the NR E-domains
through a motif with the consensus sequence LXXLL,
which facilitates direct interaction with the charge clamp.
In contrast, corepressors often have a LXXXIXXX(I/L)
motif that interacts with an overlapping surface but is
unable to ﬁt into the charge clamp (reviewed by [34]).
The variations in the primary sequences of the PPAR
LBDs results in slight diﬀerences in the cofactor interaction
surfacesandligand-inducedconformationsofthesedomains
[35, 36] and PPAR subtype-speciﬁcity is thought to be
partly imposed by diﬀerential aﬃnity of the receptors
towards the individual cofactors [37, 38]. Thus, the cofactor
expression pattern in a speciﬁc cellular context may favorPPAR Research 3
transcriptional activation of one PPAR subtype over the
others.
Probably,thetranscriptionalactivityofthePPARsshould
not be regarded as determined by a static positioning of helix
12 in either the “on” or “oﬀ” position. Rather, it appears
that ligand-binding shifts the equilibrium of the diﬀerent
helix 12 positions in the receptor population towards the
more active conformations (reviewed by [39]) [40]. Helix
12 is absolutely necessary for the activity of AF-2, and
PPAR mutants with helix 12 partly or completely deleted
are dominant negative inhibitors of PPAR signaling [41, 42].
Interestingly, the requirement for helix 12 does not appear
to equalize a requirement for ligand-binding. Recently, it
has been demonstrated that a natural PPARγ mutant that is
impervious to activation by virtually all known agonists has
intact adipogenic potential [43]. Indeed, the PPARs display
high basal transcriptional activity that can be explained by
the AF-1 in the A/B-domain and the presence of endogenous
ligands. In addition, ligand-independent recruitment of
coactivators to the AF-2 has been observed in overexpression
and in vitro studies, indicating that in addition to the
AF-1, the AF-2 also contributes to ligand-independent
transactivation. Perhaps, this is possible because the shift in
the positioning of helix 12 upon ligand-binding is not as
pronounced for the PPARs as for the steroid NRs [44, 45].
2.2. The Elusive Structure of the PPAR A/B-Domain. Com-
pared to the AF-2, the mechanisms for AF-1-mediated
transcriptional activity are less well-understood despite
several publications pointing to an important role for the
A/B-domains in maintaining PPAR subtype-speciﬁcity [15,
16, 46]. The fact that it so far has proven impossible to
crystallize a NR A/B-domain indicates that these domains
are poorly structured, a notion that has been conﬁrmed by
experiments using deuterium exchange mass spectrometry
[26], circular dichroism spectroscopy, nuclear magnetic
resonance spectroscopy [47, 48], or limited proteolysis [49,
50].Ithasbeensuggestedthatsecondarystructureformation
is an important step in AF-1-mediated transactivation and
both the PPARα [51] and glucocorticoid receptor (GR)
[47] AF-1 display α-helical characteristics in the presence
of triﬂuoroethanol, a strong α-helix stabilizing agent. Fur-
thermore, mutational analyses of the PPARα [51], GR [52,
53], and hepatocyte nuclear factor 4 (HNF-4) [54]A F - 1
domains have shown that conservation of the hydrophobic
amino acids, that potentially could be involved in α-helix
formation is especially important for the transcriptional
activity, while mutation of individual acidic amino acids
made less of an impact, suggesting that α-helix formation
is an important step in AF-1-mediated gene activation.
Interestingly, it was recently shown that mitogen-activated
protein kinase (MAPK) phosphorylation of serine 211 in
the glucocorticoid receptor A/B-domain induces formation
of secondary or tertiary structure in this region which
facilitates interaction between the AF-1 and coregulators
thereby leading to enhanced transcriptional activity [55].
Anothermodelproposesthat,asindividualcoactivatorsoﬀer
diﬀerent surfaces for unstructured activation-domains to
fold up on, distinct conformations could be induced by
the diﬀerent coactivators, thereby resulting in diﬀerential
transcriptional activity or speciﬁcity [56]. Several of the
cofactors reported to interact with NR A/B-domains have
no sequence or known structural homology, and this model
oﬀers an attractive explanation for how that is possible.
2.3. PPAR Transcriptional Activity Is Regulated by Mod-
iﬁcation of the A/B-Domain. It is well-established that
posttranslational modiﬁcations of the PPAR A/B-domains
inﬂuence the transcriptional activity of both the AF-1
and AF-2 through various mechanisms. The PPARα and
–γ A/B-domains, but not the PPARβ/δ A/B-domain, are
modiﬁed by phosphorylation. MAPK- phosphorylation of
serine 12 and 21 in the PPARα A/B-domain, enhances the
transcriptional activity by transiently increasing receptor
stability through reduced ubiquitination [32]. Oppositely,
phosphorylation of serine 76 by glycogen synthase kinase 3
(GSK3) leads to increased ubiquitination and degradation
of PPARα [93]. MAPK mediated phosphorylation of serine
82 in the PPARγ1 A/B-domain (corresponding to serine
112 in PPARγ2) has been shown to inhibit both ligand-
dependent and independent transactivation [94], the former
bydecreasingtheligand-bindingaﬃnityofthereceptor[27].
Interestingly, it was recently published that the phosphory-
lated PPARγ AF-1 domain is bound by the peptidyl-prolyl
isomerase Pin1, whereby both polyubiquitination and the
transcriptionalactivityofPPARγ isinhibited, possiblydueto
the decreased turnover rate of the receptor [95]. Oppositely,
it has also been reported that S112 phosphorylation of
PPARγ2 by a constitutively active MAPK kinase (MEK)
[96] or by cyclin-dependent kinase 9 (Cdk 9) residing
in the positive transcription elongation factor b complex
(P-TEFb) results in increased transcriptional activity [71].
Thus, it appears that the cellular and/or molecular context
determines the transcriptional eﬀect of PPARγ A/B-domain
phosphorylation. Mice homozygous for the S112A mutation
are indistinguishable from the wild types on a normal diet,
but they are signiﬁcantly more glucose tolerant in the setting
of diet-induced obesity [97], an eﬀect analogous to the
outcome of PPARγ activation by TZD treatment.In line with
phosphorylation of S112 decreasing the insulin sensitizing
actions of PPARγ, humans carrying a P115Q mutation,
that blocks phosphorylation of serine 114 (corresponding
to serine 112 in mice), are extremely obese but are also
less insulin-resistant than expected based on their degree
of obesity [98]. In addition to aﬀecting the activity of
PPARγ through regulation of MAPK, MEK has also been
reported to interact directly with PPARγ and promote its
nuclear export [99]. Recently, it was furthermore reported
that phosphorylation of serine 16 and 21 of PPARγ by
Casein-kinase-II likewise promotes shuttling of PPARγ from
the nucleus to the cytosol [100]. Besides phosphorylation,
PPARγ transactivation is also repressed by conjugation of
smallubiquitin-relatedmodiﬁer(SUMO)tolysine107inthe
A/B-domain [101].
2.4. The PPAR A/B-Domain Is Involved in the Recruitment of
Cofactors. InadditiontoregulatingthePPARtranscriptional4 PPAR Research
Table 1: Cofactors regulating PPAR activity.
Coactivator Enzymatic activity Interaction Reference
Bifunctional enzyme (BFE) Dehydrogenase α (A/B) [57]
BRG1-associated factor 60c (BAF60c) None γ (A/B) [58]
Coactivator-associated arginine methyltransferase 1 (CARM1) HMT SRC-1-3 [59]
Constitutive coactivator of PPARγ (CCPG) None γ (D) [60]
CREBP- binding protein (CBP) HAT α,γ (A/B, LBD, SRC) [61]
Hydrogen peroxide-inducible clone 5 protein (Hic5) None γ [62]
LIM domain-only protein (LMO4) None γ (D, LBD) [63]
Lipin 1 None α,P G C - 1 [ 64]
Mediator subunit 1 (MED1) None α, β/δ,γ (LBD) [65]
Mediator subunit 14 (MED14) None γ (A/B) [66]
Multiple Endocrine Neoplasia type 1 (MEN1) None γ (LBD) [67]
Multiprotein bridging factor 1 (MBF-1) None γ (D, LBD) [68]
Murine double minute 2 (MDM2) Ubiquitin ligase α, β/δ (A/B) [69]
p300 HAT α,γ (A/B, LBD, SRC) [61]
Poly ADP-ribose polymerase 2 (PARP-2) ADP-ribose polymerase γ [70]
Positive transcription elongation factor b complex (P-TEFb) Kinase γ [71]
PPARα-interacting complex 285 (PRIC285) DNA helicase α, β/δ, γ (DBD) [72, 73]
PPARα-interacting complex 320 (PRIC320) DNA helicase α [74]
PPAR-interacting protein (PRIP) None α,γ (LBD) [75]
PPARγ coactivator 1α (PGC-1α)N o n e α,γ (DBD) [76]
PPARγ coactivator 2 (PGC-2) None γ (A/B) [15]
PR domain containing 16 (PRDM16) None α,γ [77]
PRIP-interacting protein with methyltransferase domain (PIMT) HMT PRIP, CBP, MED1 [78]
Protein arginine N-methyltransferase 2 (PRMT2) HMT? γ [79]
Steroid receptor coactivator-1 (SRC-1) HAT α, β/δ, γ (LBD) [80]
Steroid receptor coactivator-2 (SRC-2) HAT α,γ (LBD) [81]
Steroid receptor coactivator-3 (SRC-3) HAT α, β/δ,γ (LBD) [81]
Tat interactive protein (Tip60) HAT γ (A/B) [82]
Thyroid hormone receptor interacting protein 3 (TRIP3) None γ (LBD) [83]
Corepressor Enzyme activity Interaction Reference
Histone deacetylase 1 (HDAC1) HDAC NCoR, SMRT [84]
Histone deacetylase 3 (HDAC3) HDAC NCoR, SMRT [85, 86]
Insulin-like growth factor-binding protein-3 (IGFBP-3) None γ [87]
Nuclear receptor corepressor 1 (NCoR) None α, β/δ, γ [88]
Receptor-interacting protein 140 (RIP140) None α,γ (LBD) [89]
Scaﬀold attachment factor B1 (SAFB1) None α, β/δ, γ [90]
Silencing mediator of retinoid and thyroid receptors (SMRT) None α, β/δ, γ [88]
Silent mating type information regulation 2 homolog 1 (SIRT1) HDAC NCoR, PGC-1 [91]
Tribbles homolog 3 (TRB3) None γ (A/B) [92]
Histone methyltransferase (HMT), Histone acetyltransferase (HAT), and Histone deactylase (HDAC).
activity by aﬀecting receptor stability, cellular compart-
mentalization, and perhaps interdomain communication in
response to the posttranslational modiﬁcation status, the
PPAR A/B-domains are involved in recruiting a handful
of cofactors. The PPARγ AF-1 is the most well-described
of the three PPAR A/B-domains and the coactivators Tat-
interacting protein 60 (Tip60) [82]a n dP P A R γ coactivator-
2( P G C - 2 )[ 15] but also the corepressor tribbles homolog
3( T R B 3 )[ 92] are recruited to PPARγ exclusively through
binding to the A/B-domain. Both PPARα and PPARγ
have been shown to bind the histone acetyl transferase
(HAT) coactivators p300 and CREBP-binding protein (CBP)
through interaction surfaces in both the A/B-and E-domains
in GST-pulldown studies [61]. The signiﬁcance of the A/B-
domain interaction was previously unknown, but we have
recently shown that recruitment of p300 and CBP is com-
promised by deletion of the PPARγ A/B-domain speciﬁcally
on the PPREs of the target genes that required AF-1 activityPPAR Research 5
to become fully activated [46]. The SWI/SNF chromatin
remodeling complex BRG1-associated factor 60c (BAF60c)
subunit which interacts directly with PPARγ likewise appear
to have the potential to bind both the A/B- and E-domains,
but the AF-1 interaction is stronger and ligand-independent
[58]. PPARα has been shown to be coactivated by binding
of the target gene product bifunctional enzyme (BFE) to the
A/B-domain [57], and the ubiquitin ligase murine double
minute 2 (MDM2) is bound by the N-terminal of all
three PPAR subtypes [69]. In addition, we have recently
demonstrated that the Mediator complex is tethered to the
PPARγ A/B-domain through the MED14 subunit and that
MED14 is required for full transcriptional activation of
PPARγ subtype-speciﬁc genes by PPARγ [102]. A complete
list of the cofactors currently known to interact with the
PPARs is shown in Table 1.
2.5. The A/B-Domains Play an Important Role in Maintaining
PPAR Subtype-Speciﬁcity. Because the A/B-domain is the
least conserved region among the PPARs, it has long been
suspected that subtype-speciﬁcity, and target gene selectivity
is completely or partly mediated through this domain. This
hypothesis has been investigated by deleting the A/B-domain
orbyconstructingchimericPPARswheredomainshavebeen
swapped between the subtypes.
Despite the undisputed observation that the PPARα and
-γ A/B-domains are potent transactivators when expressed
as GAL4-fusion proteins [51] there has been controversy
regarding the physiological importance of the activity of
the PPAR A/B-domains. Deletion of the A/B-domain was
reported to have no eﬀect [82, 103] or to signiﬁcantly
decrease PPAR-mediated expression from a reporter plasmid
in transient transfections [51]. Interestingly, deletion of the
A/B-domain aﬀected the transcriptional activity of PPARα
diﬀerentially depending on the target gene promoter used
in the reporter construct. One study employed the acyl-
CoA oxidase promoter and found that the A/B-domain
contributed signiﬁcantly to the transcriptional activity of
PPARα [51], while another study showed that luciferase
expression driven by the cytochrome P450 4A6 promoter
was completely unaﬀected by deletion of the AF-1 [103].
We have recently on a global scale shown that deletion of
the PPARγ A/B-domain selectively decreases the transacti-
vation potential of PPARγ on the highly subtype-speciﬁc
target genes. We found that out of 257 PPARγ-induced
genes only 25 are dependent on the PPARγ A/B-domain
to become fully activated in the presence of the TZD
rosiglitazone. The A/B domain dependent genes are the
highly PPARγ selective target genes many of which are
involved in lipid storage. Notably, in the absence of synthetic
agonist, transactivation of this subgroup of genes in par-
ticular relies almost exclusively on the PPARγ A/B-domain
[46].
The importance of the PPAR A/B-domains in maintain-
ing subtype-speciﬁcity has been indicated by several studies
showing that these domains are not interchangeable. Thus,
although both the α and γ A/B-domains contain potent
activationfunctions[51],theycannotfunctionallysubstitute
foreachotherasevidencedbytheobservationthatachimera
consisting of the PPARα A/B-domain and the PPARγ CDE-
domains is able to transactivate the PPARγ selective target
genes similar to that of PPARγCDE [46]. However, the A/B-
domains of PPARγ and PPARα canimpose a partial subtype-
speciﬁc activation in the context of a noncognate receptor.
Spiegelman and coworkers showed that swapping the PPARγ
A/B-domain on to the nonadipogenic PPARβ/δCDE con-
ferred adipogenic potential to this receptor subtype [15].
Subsequently, Tontonoz and coworkers reported that the
PPARA/B-domainsfunctiontorestricttargetgeneactivation
in the context of the cognate receptor and showed that
A/B-domain deleted PPARβ/δ (PPARβ/δCDE) can induce
adipogenesis. This study thereby raised the question as to
what degree the adipogenic potential of the PPARγ A/B-
domain-PPARβ/δCDEchimerausedintheSpiegelmanstudy
arose by the addition of the PPARγ A/B-domain or the lack
of the PPARβ/δ A/B-domain [13, 16]. In agreement with the
A/B-domains conferring subtype-speciﬁcity to the PPARs in
part by limiting nonselective target gene activation, we have
shown that compared to the full length receptors, the A/B-
domain deleted PPARαCDE and -γC D Ea r ef a rb e t t e rt r a n s -
activators of the noncognate highly subtype selective PPAR
target genes normally activated by the opposite subtype.
However, reminiscent of the Spiegelman data we also found
thataddition ofthePPARαA/B-domaingreatlyenhancesthe
ability of PPARγCDE to activate a PPARα speciﬁc target gene
[46]. Thus, it appears that the A/B-domains contribute to
maintaining PPAR subtype-speciﬁcity by both potentiating
activation of the highly subtype selective target genes, and
by restricting nonselective target gene activation exclusively
in the context of the cognate CDE domains. By contrast, the
A/B-domain plays only a minor role in the activation of the
target genes shared between the subtypes (Figure 1).
3. Genome-Wide Approaches to Mapping PPAR
Subtype-SpeciﬁcTransactivation
The PPAR transcriptome in cells and tissues has been
mappedbyectopicallyexpressingaparticularsubtypeand/or
treating with a speciﬁc agonist and mapping the changes
in gene expression using array technology. More recently
the combination of chromatin immunoprecipitation (ChIP)
with microarray analysis (ChIP-chip), high throughput
sequencing (ChIP-seq), or with pair end-tagging sequencing
(ChIP-PET) has allowed the mapping of the PPAR cistrome
incellsandtissuesfollowingvarioustreatments.Theseglobal
techniques have led to important insights into the role of the
diﬀerent PPAR subtypes in the regulation of metabolism and
diﬀerentiation and into the action of PPAR agonists.
3.1.ExpressionArrayStudies. Althoughmicroarraystudiesof
NIH-3T3 ﬁbroblast overexpressing PPARβ/δ have conﬁrmed
that this PPAR subtype rightfully is recognized as being
an inducer of genes involved in energy expenditure and β-
oxidation of fatty acids [16] it appears that at least in insulin-
resistant (db/db) mice, activation of this pathway by PPARδ-
speciﬁc agonists is limited to the muscles. Administration of
PPARβ/δ agonist ameliorates both muscle and liver insulin6 PPAR Research
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Figure 1: The PPAR A/B-domains potentiate transactivation of the highly subtype selective target genes. Illustration of the diﬀerential
requirement for the PPAR A/B-domains in the transactivation of highly subtype selective and non-subtype selective target genes. The PPAR
subtype speciﬁc target genes are generally expressed at very low levels in the absence of PPARs, but expression is dramatically increased upon
introduction of full length exogenous PPAR. The activities of the PPAR A/B-domains are necessary to obtain this potent induction of the
highly subtype speciﬁc target genes, presumably by facilitating recruitment and tethering of histone acetylase complexes (HATs) and the
Mediator complex. Conversely, non-subtype selective PPAR target genes are usually already expressed at high levels in the absence of PPARs,
and their expression levels are only increased by a few fold in response to ectopic PPAR expression. The PPAR A/B-domains appear to be
dispensable for transactivation of this group of target genes.
resistance in db/db mice by lowering the hepatic glucose
output, increasing glucose disposal, and inhibiting fatty
acid release from the adipose tissue. Surprisingly however,
the expression arrays only detected induction of carnitine
palmitoyltransferase 1 (Cpt1), a key gene in fatty acid β-
oxidation, in the muscles, whereas the pathways responsible
fortheincreasedglucosedisposalappearedtobehepaticfatty
acid synthesis and pentose phosphate shunt that generates
NADPH to provide reducing power for lipid synthesis [104].
Consistent with previous reports [105], PPARβ/δ agonist
treatment did lead to increased β-oxidation rates in the
muscles,suggestingthatPPARβ/δ promoteinsulinsensitivity
by consuming glucose through induction of hepatic fat-
production in combination with a counterbalancing fat
burning in muscle [104]. A recent study comparing hepatic
gene regulation between wild type and PPARβ/δ -or PPARα
knockoutmiceshowedthatwhilePPARαexpressionishighly
upregulated during fasting, Pparβ/δ mRNA is downregu-
lated. In accordance with this ﬁnding, the diﬀerences in gene
expression between the wild type and PPARβ/δ knockout
mice were more pronounced in the fed state but surprisingly
a relatively large subset of genes were downregulated in a
PPARβ/δ-dependent manner during the fast. Interestingly,
there is only limited overlap between the hepatic genes regu-
lated in a PPARα or PPARβ/δ-dependent manner in the fed
state, while a large proportion of the target genes appear to
be regulated by both subtypes in the fasted state. It is evident
that some of the diﬀerential eﬀects on liver gene expression
in the two knockout mouse models may be due to indirect
eﬀects imposed by other tissues; however, in agreement
with the general perception of PPARβ/δ being an inhibitor
of inﬂammation, pathway analyses showed that several
gene sets involved in these processes were enriched in the
knockoutmiceinthefedstate.Inthefastedstate,theelectron
transport and oxidative phosphorylation pathways were
decreased and in both metabolic states deletion of PPARβ/δ
resulted in downregulation of genes involved in lipoprotein
metabolism and carbohydrate metabolism, which included
glycogen metabolism, glycolysis, gluconeogenesis, and the
pentose phosphate pathway [106]. In agreement with the
conclusion from the db/db mouse study indicating that
PPARβ/δ is an important regulator of glucose disposal and
utilization [104], these changes in gene expression resulted
in signiﬁcantly increased fasting plasma glucose levels in
the PPARβ/δ knockout mice [106]. Besides studies of the
PPARα knockout mice [106, 107], other approaches to
determinethePPARαtranscriptome includes overexpression
studies in ﬁbroblasts [16], exposure of hepatoma cell lines
to synthetic PPARα agonist [108], and in vivo examinations
of the alterations in the gene expression pattern of mouse
and monkey liver [109, 110] and mouse intestine [111]i n
response to agonist treatment. These studies unanimouslyPPAR Research 7
report that PPARα is the major inducer of β-oxidation
in these tissues. In addition, it has also been reported
that PPARα function to repress amino acid catabolism
[112].
The PPARγ transcriptome of the adipogenic 3T3-L1
cell line has been characterized in several expression array
studies because of the high endogenous expression level
of PPARγ and the observation that white adipose tissue
is essential for the insulin sensitizing eﬀects of the TZD
PPARγ agonists [113, 114]. Studies using these agonist to
drive the diﬀerentiation of preadipocytes show that the
TZDs are potent activators of adipogenesis and induce or
enhance the expression of adipocyte speciﬁc markers and
genes involved in lipid storage and transport, but also lipid
hydrolysis and oxidation [115, 116]. Interestingly however,
when mature adipocytes are exposed to TZDs for a few
hours up to a couple of days, it leads to decreased expression
of both PPARγ itself and of lipid storage and adipokine
genes while fatty acid activation and degradation is induced
[116, 117]. The global eﬀects of TZD treatment on gene
expression has also been investigated in macrophages [118],
coloncancercells[119],aorta[120],anddendriticcells[121]
with regulation of genes involved in lipid metabolism and
inﬂammation being a consistent ﬁnding in these studies.
Other approaches to annotate the PPARγ transcriptome
include analysis of NIH-3T3 ﬁbroblasts transduced with
retrovirus encoding PPARγ2[ 16, 122] and adenoviral over-
expression of PPARγ1 in the liver of PPARα knockout mice
for2–6days[20].Thelatterresultedinhepaticsteatosis,thus
underscoring the lipogenic potential of PPARγ.I no r d e rt o
increase the chances of identifying genes targeted directly by
PPARγ as opposed to genes being diﬀerentially expressed as
a consequence of secondary regulation, we made use of acute
adenoviral expression of the PPARs in NIH-3T3 ﬁbroblasts,
which have very low levels of endogenous PPARs [11]. This
system allows us to induce rapid expression of the PPARs
and subsequently evaluate the immediate eﬀects on target
geneactivityatthemRNAlevelwithin8haftertransduction,
whereby secondary eﬀects (e.g., induction of endogenous
PPARs) on gene expression were minimized. By combining
this cellular system with expression array analysis, we found
that ectopic PPARγ2 expression in combination with TZD
treatment acutely activated a large number of known and
novel target genes in the NIH-3T3 cells. Both expression of
genes involved in lipid anabolic and catabolic pathways were
induced but the net outcome was lipid accumulation [46].
These results corroborate previous ﬁndings from our lab
that when expressed at adipocyte levels, PPARγ2i sas t r o n g
transactivator capable of activating most PPAR target genes,
even if other subtypes expressed at the same level would be
better activators [11].
3.2. ChIP-Chip and ChIP-Seq Studies. The generation of
genome-wide proﬁles of PPAR, RXR, and cofactor occu-
pancy using the ChIP-chip, ChIP-seq, and ChIP-PET tech-
nologies has signiﬁcantly increased the understanding of
PPAR-mediated transactivation. First, these studies have
shown that most target genes have multiple PPAR binding
sites not only in the proximal promoter region but also
in introns and at distant positions up- and downstream
of the gene. Notably, about 50% of all PPAR:RXR-binding
sites are found in introns. This distributions of binding sites
reﬂects that of most other nuclear receptors [123–125]a n d
of the several other transcription factors [126–128]. While
these studies provide invaluable help in determining the
position of binding sites, they also complicate the picture
of functional PPREs and underscore the weaknesses of
traditional promoter and enhancer characterization, where
often only the proximal promoter or genomic sequences
immediately upstream of the transcription start site are
cloned in front of a luciferase reporter.
The ﬁrst PPAR cistrome to be published was that of
PPARγ in diﬀerentiating and mature 3T3-L1 adipocytes as
mapped by ChIP-seq [129] and ChIP-chip [130]. Subse-
quently, the PPARγ cistrome in 3T3-L1 cells has also been
mapped by others using ChIP-chip [131], ChIP-seq [132],
and ChIP-PET [133]. The mappings revealed between 2730
and 7000 genomic PPARγ binding sites, depending on the
method and false discovery rate employed. Notably, all genes
encodingproteinsinvolvedinfattyacidhandlingandstorage
as well as lipolysis were found to have adjacent PPARγ:RXR
binding sites, but surprisingly this was also true for most
genes encoding enzymes involved in steroid metabolism
[133], glycolysis, the pentose phosphate pathway, and the
TCA cycle [129, 131]. Interestingly, a signiﬁcant overlap
between PPARγ:RXR binding sites and binding sites of
CCAT/enhancer binding protein (C/EBP) α and -β was
found [129, 130] indicating that the cooperativity between
PPARγ andmembersoftheC/EBPfamilyintheregulationof
adipocyte gene expression (reviewed previously [134]) takes
place on a much larger scale than previously anticipated.
A recent study proﬁling the PPARγ cistrome in pri-
mary mouse macrophages found that there was only very
limited overlap between the genomic sites bound by the
receptor in this cell type and in adipocytes. Interestingly,
the transcription factor PU.1, which is involved in monocyte
development and not expressed in adipocytes, was enriched
at the macrophage speciﬁc sites. This study thus addresses
the intriguing question of how cell type-speciﬁc PPARγ
transactivation is achieved at the level of chromatin binding
and suggests that tissue-speciﬁc factors may play a role in
facilitatingPPARγ bindingtothetissueselectivebindingsites
[132].
So far, genome-wide cistromes are not available for
other PPAR subtypes, but recently PPARα binding sites in a
human hepatoma cell line was mapped by ChIP-chip using
an array covering promoter regions from 7.5kb upstream
to 2.5kb downstream of the transcription start site. This
study showed increased binding of PPARα to 4220 genomic
regions in response to agonist treatment [135]. The group of
genes assigned to these binding sites that were upregulated
as determined by microarray analysis, clustered as being
involved in sterol and lipid biosynthetic pathways, which
is surprising given the general perception of PPARα as an
inducer of lipid degradation. The downregulated genes were
involved in innate and humoral immune response, which
is consistent with the well-described anti-inﬂammatory
activity of PPARα (Reviewed previously [5]).8 PPAR Research
4.SummaryandPerspectives
As described in this paper, several molecular mechanisms
conferring subtype-speciﬁcity to the PPARs or leading to
preferential activation of a speciﬁc PPAR subtype in a certain
cellularcontexthavebeenelucidated.(1)ThePPARsubtypes
bind to the individual genomic PPREs with diﬀerential aﬃn-
ity. (2) The PPARs are activated by diﬀerent ligands. (3) The
PPAR subtypes display diﬀerential aﬃnity towards various
cofactors. (4) PPAR transcriptional activity is modulated
by subtype-speciﬁc posttranslational modiﬁcations. (5) The
PPAR A/B-domains potentiate subtype-speciﬁc activation
of target genes while restricting nonselective target gene
activation.
Most likely, PPAR subtype-speciﬁcity is maintained
through the concerted eﬀects of the regulatory mechanisms
exerted by the individual PPAR domains or communicating
PPAR and RXR domains. However, the current knowledge
strongly suggests that the relative importance of these con-
tributions is diﬀerential and that especially the A/B-domains
are important mediators of PPAR subtype-speciﬁcity. Future
studies should aim at pinpointing the exact sections of the
A/B-and E-domains, and potentially the D-domain, that are
involved in maintaining PPAR subtype-speciﬁcity and to
fully elucidate the molecular mechanisms underlying this
activity.
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